CLINICAL_TRIALS
trial_result
· 2016-08-02
Clinical Trial Update: A Study of Erlotinib (Tarceva) in Participants With Non-Small Cell Lung Cancer (NSCLC) [Phase 2]
Summary
A Phase 2 study of Erlotinib (Tarceva) in participants with non-small cell lung cancer has completed, and results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Hoffmann-La Roche | Conditions: Non-Squamous Non-Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2016-08-02